comparemela.com
Home
Live Updates
Database Consortium - Breaking News
Pages:
2
3
4
5
6
7
8
Latest Breaking News On - Database consortium - Page 1 : comparemela.com
Higher T-Cell Inflamed GEP Values Are Positively Associated with Outcomes For Pembrolizumab/Axitinib in ccRCC
Higher T-cell inflamed GEP values were positively associated with clinical outcomes for pembrolizumab plus axitinib in advanced clear cell RCC.
United states
Brian rini
International metastatic
Vanderbilt ingram cancer center
Ingram professor of cancer research
Database consortium
Highert cell
Clinical trials
Ingram professor
Cancer research
Baseline patient
North america
Western europe
Findings from
Lenvatinib/Pembrolizumab Yields Greater Clinical Benefit vs Sunitinib Regardless of Biomarker Subtypes in ccRCC
Lenvatinib plus pembrolizumab displayed a superior clinical benefit vs sunitinib irrespective of patient biomarker subtype in advanced clear cell RCC.
United states
Dana farber cancer institute
Toni choueiri
Nancy kohlberg
Memorial sloan kettering cancer center
International metastatic
Database consortium
Professor of medicine at harvard medical school
Lank center
Genitourinary oncology at dana farber cancer institute
Genitourinary oncology
Kidney cancer program
Harvard cancer center
Nancy kohlberg chair
Harvard medical school
Western europe
ASCO 2024: Belzutifan in Patients with Advanced Clear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 2 LITESPARK-013 Study
ASCO 2024, advanced clear cell renal cell carcinoma (ccRCC), Belzutifan, LITESPARK-013 Study, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).
United states
Georgetown university
District of columbia
Michael atkins
Michaelb atkins
University of toronto
Georgetown lombardi comprehensive cancer center
Department of medical oncology
Database consortium
Georgetown university medical center
Merck sharp dome
Society of urologic oncology
International metastatic
American society of clinical oncology
Clinical oncology
Annual meeting
DFF332 Elicits Efficacy and Is Safe in Advanced Clear Cell RCC
The small molecule inhibitor DFF332 elicited clinical activity and had a tolerable safety profile in patients with advanced clear cell renal cell carcinoma.
United states
Sumanta kumar pal
Bladder cancer disease team
Kidney cancer program
Database consortium
International metastatic
Medical oncology
Therapeutics research
Hope comprehensive cancer center
ASCO: Merck KGaA s Bavencio combo misses survival mark in RCC
Although the overall survival miss won't cost Bavencio its FDA approval, it puts the drug further behind rival PD-1 combos from Merck & Co. and BMS.
New york
United states
Merck keytruda
Keytruda lenvima
Peter guenter
Exelixi cabometyx
Merck kgaa bavencio
International metastatic
Merck kgaa
Bristol myers squibb
Merck kga
American society of clinical oncology
Database consortium
Merck co
American society
Clinical oncology
vimarsana © 2020. All Rights Reserved.